CXCL1 stimulates migration and invasion in ER ‑negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis.

In conclusion, the present study demonstrated that CXCL1 is highly expressed in ER‑negative BC, and stimulates BC cell migration and invasion via the ERK/MMP2/9 pathway. Therefore, CXCL1 may serve as a potential therapeutic target in ER‑negative BC.
PMID: 31322183 [PubMed - as supplied by publisher]

Source: International Journal of Oncology - July 14, 2019 Category: Cancer & Oncology Authors: Yang C, Yu H, Chen R, Tao K, Jian L, Peng M, Li X, Liu M, Liu S Tags: Int J Oncol Source Type: research